Patient-derived organoids (PDOs) have emerged as powerful tools in precision oncology by allowing researchers to test therapies on living tumor models that closely mirror a patient’s cancer. But bringing PDO-based drug screening into the clinic has remained difficult due to the requirement of large numbers of organoids and lengthy expansion time.
In this exclusive interview, researchers from HUB Organoids and Yamaha Motor discuss how they developed a miniaturized organoid screening workflow capable of generating robust drug-response data using only a fraction of the biological material required by conventional methods.
Download this article to learn:
- How automated image-based selection enables reliable drug screening with as few as 10 organoids per condition
- How miniaturized workflows reduce biological material requirements by 30- to 50-fold
- Why low-input organoid screening could accelerate personalized cancer treatment and oncology drug development
